Zobrazeno 1 - 10
of 101
pro vyhledávání: '"MASANOBU ENOMOTO"'
Autor:
Kenta Kasahara, Masanobu Enomoto, Ryutaro Udo, Tomoya Tago, Junichi Mazaki, Tetsuo Ishizaki, Tesshi Yamada, Yuichi Nagakawa, Kenji Katsumata, Akihiko Tsuchida
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Several studies have demonstrated that the preoperative Glasgow prognostic score (GPS) and modified GPS (mGPS) reflected the prognosis in patients undergoing curative surgery for colorectal cancer. However, there are no reports on
Externí odkaz:
https://doaj.org/article/3b528f05042c4a2c89963d83ad203ddc
Autor:
Keisuke Miwa, Eiji Oki, Masanobu Enomoto, Keisuke Ihara, Koji Ando, Fumihiko Fujita, Masahiro Tominaga, Shinichiro Mori, Goro Nakayama, Mototsugu Shimokawa, Hiroshi Saeki, Hideo Baba, Masaki Mori, Yoshito Akagi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) o
Externí odkaz:
https://doaj.org/article/1d3bf1bb74fc4caa92cb2f4e1ca49d61
Autor:
Junichi Mazaki, Kenji Katsumata, Kenta Kasahara, Tomoya Tago, Takahiro Wada, Hiroshi Kuwabara, Masanobu Enomoto, Tetsuo Ishizaki, Yuichi Nagakawa, Akihiko Tsuchida
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background A large number of patients suffer recurrence after curative resection, and mortality from colon cancer remains high. The role of systemic inflammatory response, as reflected by neutrophil-to-lymphocyte ratio (NLR), in cancer recur
Externí odkaz:
https://doaj.org/article/9016d999387149f3a1aec3554a1edafc
Autor:
Hiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yuji Negoro, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Hiroyuki Okuyama, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Toshikazu Moriwaki
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundPrimary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently,
Externí odkaz:
https://doaj.org/article/1b5c529d863847208161fdacda20bb31
Autor:
Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Yoshihiro Okita, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of RE
Externí odkaz:
https://doaj.org/article/62fbb44c692c4df88be7192d21a1ba7b
Autor:
Toru Sakurai, Kenji Katsumata, Ryutaro Udo, Tomoya Tago, Kenta Kasahara, Junichi Mazaki, Hiroshi Kuwabara, Hideaki Kawakita, Masanobu Enomoto, Tetsuo Ishizaki, Yukako Nemoto, Yoshiaki Osaka, Yuichi Nagakawa, Masahiro Sugimoto, Akihiko Tsuchida
Publikováno v:
Metabolites, Vol 12, Iss 1, p 59 (2022)
This study aimed to validate and reanalyze urinary biomarkers for detecting colorectal cancers (CRCs). We previously conducted urinary metabolomic analyses using capillary electrophoresis-mass spectrometry and found a significant difference in variou
Externí odkaz:
https://doaj.org/article/91670ea66898499c935f57ef070a8af5
Autor:
Yasuharu Mori, Kenji Katsumata, Shouji Suzuki, Daisuke Matsuda, Tomonori Hara, Yasuharu Hayashida, Masanobu Enomoto, Tatehiko Wada, Akihiko Tsuchida, Tatsuya Aoki, Tsuyoshi Saitou, Jun Matsubayashi, Hiroshi Kusama
Publikováno v:
Case Reports in Gastroenterology, Vol 4, Iss 3, Pp 484-491 (2010)
Our case was a 65-year-old male, with the chief complaints of diarrhea and abdominal distention. Three years earlier, the patient had undergone transcatheter arterial embolization and radiofrequency treatment based on a diagnosis of hepatocellular ca
Externí odkaz:
https://doaj.org/article/d48eec9b302548148385a126eb7a8386
Autor:
Tetsushi Nakajima, Kenji Katsumata, Hiroshi Kuwabara, Ryoko Soya, Masanobu Enomoto, Tetsuo Ishizaki, Akihiko Tsuchida, Masayo Mori, Kana Hiwatari, Tomoyoshi Soga, Masaru Tomita, Masahiro Sugimoto
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 3, p 756 (2018)
Colorectal cancer (CRC) is one of the most daunting diseases due to its increasing worldwide prevalence, which requires imperative development of minimally or non-invasive screening tests. Urinary polyamines have been reported as potential markers to
Externí odkaz:
https://doaj.org/article/c006165d28324abe80b983a9e16e3038
Autor:
Ryo Ohta, Takeshi Yamada, Masato Nakamura, Masanobu Enomoto, Makoto Takahashi, Hajime Yokomizo, Chihiro Kosugi, Kei Ishimaru, Hiromichi Sonoda, Hidekazu Kuramochi, Yoichiro Yoshida, Shinji Furuya, Keiji Hirata, Hiroshi Yoshida, Keijiro Nozawa, Yojiro Hashiguchi, Hideyuki Ishida, Keiji Koda, Kenji Katsumata, Kazuhiro Sakamoto
Publikováno v:
Digestion. :1-10
Introduction: Regorafenib is a multi-kinase inhibitor approved for patients with metastatic colorectal cancer (mCRC) who were previously treated with standard therapies. A few reports showed the impact of KRAS mutation on therapeutic efficacy of rego
Autor:
Tomokazu Okazaki, Takuya Omotehara, Shinichi Kawata, Takahiro Amano, Masanobu Enomoto, Yuichi Nagakawa, Masahiro Itoh
Publikováno v:
Diseases of the Colon & Rectum; Jan2024, Vol. 67 Issue 1, p120-128, 9p